Clinically Approved Monoclonal Antibodies–Based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinically Approved Monoclonal Antibodies–Based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care
Authors
Keywords
-
Journal
CLINICAL THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.clinthera.2023.10.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hyperglycaemia following immune checkpoint inhibitor therapy‐ incidence, aetiology and assessment.
- (2023) K. Mulla et al. DIABETIC MEDICINE
- Sintilimab-induced autoimmune diabetes: A case report and review of the literature
- (2022) Jing Yang et al. World Journal of Clinical Cases
- Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature
- (2022) Juan Yan et al. Annals of Translational Medicine
- A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
- (2021) Lili Wu et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report
- (2021) Anton Nikouline et al. Canadian Journal of Emergency Medicine
- Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer
- (2021) Xiaofei Huang et al. MEDICINE
- Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
- (2021) Laura Boswell et al. Journal of Diabetes Investigation
- Potential therapeutic effects of different mouthwashes for alleviation and treatment of oral complications of 5-fluorouracil-based chemotherapy in patients with colon cancer
- (2021) Anmar Al-Taie et al. European Journal of Hospital Pharmacy-Science and Practice
- A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab
- (2021) Sonya K. Kedzior et al. American Journal of Case Reports
- Diabetes and Cancer: Risk, Challenges, Management and Outcomes
- (2021) Rabia K. Shahid et al. Cancers
- Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
- (2020) Z. Quandt et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Simultaneous development of Graves’ disease and type 1 diabetes during anti‐programmed cell death‐1 therapy: A case report
- (2020) Susumu Kurihara et al. Journal of Diabetes Investigation
- Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review
- (2020) A Ram Hong et al. Frontiers in Endocrinology
- Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab
- (2020) Nikhila Kethireddy et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
- (2020) Angelos Kyriacou et al. CLINICAL MEDICINE
- Anti–PD-1 Therapy Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma
- (2020) Raynald A. Samoa et al. DIABETES CARE
- Impact of clinical pharmacy recommendations and patient counselling program among patients with diabetes and cancer in outpatient oncology setting
- (2020) Anmar Al‐Taie et al. EUROPEAN JOURNAL OF CANCER CARE
- Rapid onset type 1 diabetes with anti-PD-1 directed therapy
- (2020) Karen Yun et al. Oncotarget
- New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature
- (2020) Lukas Delasos et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab
- (2020) Soichiro Mae et al. JOURNAL OF EMERGENCY MEDICINE
- Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
- (2020) Mohamed A. Alfaleh et al. Frontiers in Immunology
- Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
- (2020) Liang Wen et al. Frontiers in Immunology
- Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review
- (2020) Zhe Zhao et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 2018 FDA drug approvals
- (2019) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Case of fulminant type 1 diabetes induced by the anti‐programmed death‐ligand 1 antibody, avelumab
- (2019) Yui Shibayama et al. Journal of Diabetes Investigation
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma
- (2019) C. Sakaguchi et al. Current Oncology
- Diabetes mellitus secondary to treatment with immune checkpoint inhibitors
- (2019) V. Venetsanaki et al. Current Oncology
- Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy
- (2019) M. Bastin et al. DIABETES & METABOLISM
- Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report
- (2019) Ryuya Edahiro et al. Thoracic Cancer
- Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event
- (2019) Mesut Yilmaz JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Rapid onset type 1 diabetes associated with the programmed cell death‐1 inhibitor pembrolizumab
- (2019) Veronica Boyle et al. INTERNAL MEDICINE JOURNAL
- Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
- (2019) Jin Sothornwit et al. Frontiers in Endocrinology
- Demonstrating the value of the oncology pharmacist within the healthcare team
- (2019) Eve M Segal et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia
- (2019) Naoko Yamamoto et al. INTERNAL MEDICINE
- Case of acute‐onset type 1 diabetes induced by long‐term immunotherapy with nivolumab in a patient with mucosal melanoma
- (2019) Takeo Maekawa et al. JOURNAL OF DERMATOLOGY
- Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
- (2019) Ashray Gunjur et al. Journal for ImmunoTherapy of Cancer
- An Overview of Monoclonal Antibodies
- (2019) Virginia Bayer Seminars in Oncology Nursing
- Fulminant diabetes due to immune checkpoint inhibitors in the emergency department
- (2019) Olivier Peyrony et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level
- (2019) Masaaki Miyauchi et al. Journal of Diabetes Investigation
- Immune checkpoint inhibitors and endocrine side effects, a narrative review
- (2019) L Agrawal et al. POSTGRADUATE MEDICINE
- Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports
- (2019) Marco Zezza et al. BMC Endocrine Disorders
- ENDOCRINE SIDE-EFFECTS OF NEW ANTICANCER THERAPIES: OVERALL MONITORING AND CONCLUSIONS
- (2018) F. Castinetti et al. ANNALES D ENDOCRINOLOGIE
- Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
- (2018) Marie-Léa Gauci et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis
- (2018) R. Barua et al. CLINICAL ONCOLOGY
- Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development
- (2018) Meric Ovacik et al. CTS-Clinical and Translational Science
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Diabetes associated with immune checkpoint inhibition: presentation and management challenges
- (2018) A Galligan et al. DIABETIC MEDICINE
- Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
- (2018) Pedro Iglesias European Journal of Internal Medicine
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab
- (2018) Toshikazu Omodaka et al. JOURNAL OF DERMATOLOGY
- Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma
- (2018) Akira Takahashi et al. MELANOMA RESEARCH
- Immunotherapy-induced autoimmune diabetes and concomitant hypophysitis
- (2018) Melissa Sum et al. Pituitary
- Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
- (2018) Kanako Sakurai et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Bispecific antibodies: design, therapy, perspectives
- (2018) Sergey Sedykh et al. Drug Design Development and Therapy
- Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
- (2018) Simon A. Hinke et al. Molecular Metabolism
- Expert opinion on immunotherapy induced diabetes
- (2018) Sarra Smati et al. ANNALES D ENDOCRINOLOGIE
- Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring
- (2018) Francesco Tassone et al. ACTA DIABETOLOGICA
- Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Diabetic ketoacidosis induced by a single dose of pembrolizumab
- (2018) Julian Maamari et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient
- (2018) Sicheng Li et al. MEDICINE
- Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report
- (2018) Yukihisa Hatakeyama et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma
- (2017) Matthew A Smith-Cohn et al. Immunotherapy
- A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient
- (2017) Manuel Araújo et al. Immunotherapy
- The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis
- (2017) Ebtihag O. Alenzi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non–Small Cell Lung Cancer
- (2017) Giulia C. Leonardi et al. JOURNAL OF IMMUNOTHERAPY
- Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
- (2017) Yuko Usui et al. Journal of Thoracic Oncology
- Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma
- (2017) Aikaterini Tsiogka et al. MELANOMA RESEARCH
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity
- (2017) Pui Ying Chan et al. Pigment Cell & Melanoma Research
- Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature
- (2017) Laura Hickmott et al. Targeted Oncology
- Implementation and evaluation of medicine and therapeutic information service by clinical pharmacists in oncology care setting
- (2017) Himanshu Patel et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
- (2017) Pouyan N. Changizzadeh et al. Journal for ImmunoTherapy of Cancer
- Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
- (2017) James Luke Godwin et al. Journal for ImmunoTherapy of Cancer
- Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis
- (2017) P.W. Atkins et al. DIABETES & METABOLISM
- Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
- (2016) Sung Hye Kong et al. ACTA DIABETOLOGICA
- Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma
- (2016) G. H. Teló et al. ANNALS OF ONCOLOGY
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- (2016) Young Kwang Chae et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside
- (2016) Chantal Kuhn et al. Immunotherapy
- Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma
- (2016) Wataru Munakata et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient
- (2016) Yukiko Teramoto et al. JOURNAL OF DERMATOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
- (2016) Yuka Miyoshi et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
- (2016) Jared R. Lowe et al. Journal for ImmunoTherapy of Cancer
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Glycemic Variation in Tumor Patients with Total Parenteral Nutrition
- (2015) Guo-Hui Li et al. CHINESE MEDICAL JOURNAL
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
- (2015) Caroline Gaudy et al. DIABETES CARE
- Assessing the Effectiveness of Pharmacist-Directed Medication Therapy Management in Improving Diabetes Outcomes in Patients With Poorly Controlled Diabetes
- (2015) Jeannine S. Skinner et al. DIABETES EDUCATOR
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
- (2015) K. K. Tsilidis et al. BMJ-British Medical Journal
- Research and development of therapeutic mAbs: An analysis based on pipeline projects
- (2015) Xiaomei Geng et al. Human Vaccines & Immunotherapeutics
- Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
- (2015) K. K. Tsilidis et al. BMJ-British Medical Journal
- Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades
- (2014) Tze-Minn Mak et al. ANTIVIRAL RESEARCH
- Novel Diabetes Autoantibodies and Prediction of Type 1 Diabetes
- (2013) Janet M. Wenzlau et al. Current Diabetes Reports
- Type 1 diabetes
- (2013) Mark A Atkinson et al. LANCET
- Incidences of diabetes and prediabetes among female adult breast cancer patients after systemic treatment
- (2013) Guang-yan Ji et al. MEDICAL ONCOLOGY
- Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy
- (2013) Suk-young Lee et al. SUPPORTIVE CARE IN CANCER
- Diabetes mellitus and cancer risk: Review of the epidemiological evidence
- (2012) Kentaro Shikata et al. CANCER SCIENCE
- Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study
- (2012) J.-P. Feng et al. Colorectal Disease
- Monoclonal antibody therapeutics: history and future
- (2012) Nicholas APS Buss et al. CURRENT OPINION IN PHARMACOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center
- (2011) J. M. Valgus et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic
- (2011) Megan McKee et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Hyperglycemia During Chemotherapy for Hematologic and Solid Tumors Is Correlated With Increased Toxicity
- (2010) Antonella Brunello et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Effect of Adding Pharmacists to Primary Care Teams on Blood Pressure Control in Patients With Type 2 Diabetes: A randomized controlled trial
- (2010) S. H. Simpson et al. DIABETES CARE
- B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies
- (2010) Waka Lin et al. NUCLEIC ACIDS RESEARCH
- Guidelines to cell engineering for monoclonal antibody production
- (2009) A. Rita Costa et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Monoclonal antibodies for cancer immunotherapy
- (2009) Louis M Weiner et al. LANCET
- Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus
- (2008) Bethany B. Barone JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now